vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $17.08 and traded as low as $16.60. vTv Therapeutics shares last traded at $16.99, with a volume of 1,403 shares traded.
Analyst Ratings Changes
VTVT has been the topic of a number of recent research reports. HC Wainwright initiated coverage on shares of vTv Therapeutics in a report on Wednesday, April 9th. They issued a "buy" rating and a $36.00 target price on the stock. Wall Street Zen initiated coverage on shares of vTv Therapeutics in a report on Wednesday, April 16th. They issued a "sell" rating on the stock.
Check Out Our Latest Analysis on vTv Therapeutics
vTv Therapeutics Price Performance
The stock's fifty day simple moving average is $16.98 and its 200-day simple moving average is $17.32. The stock has a market cap of $53.50 million, a P/E ratio of -5.57 and a beta of 0.58.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.04).
Hedge Funds Weigh In On vTv Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in VTVT. JPMorgan Chase & Co. acquired a new position in shares of vTv Therapeutics during the fourth quarter worth approximately $25,000. Geode Capital Management LLC boosted its position in shares of vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock worth $158,000 after buying an additional 1,327 shares during the period. Finally, Connective Capital Management LLC acquired a new position in shares of vTv Therapeutics during the first quarter worth approximately $162,000. 17.51% of the stock is currently owned by institutional investors and hedge funds.
vTv Therapeutics Company Profile
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Featured Stories
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
